CancerIQ
United States
- Chicago, Illinois
- 04/03/2022
- Series B
- $14,000,000
About Us
CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease.
Why Work with Us?
We have quietly built a market-leading product that patients, providers, and healthcare executives all love. With new funding and new strategic partners, we're on pace for rapid growth. We've a team of clever, scrappy, and mission-driven individuals making a huge impact in cancer prevention - so if you're passionate about healthcare - join our team.
- Industry Hospital & Health Care
- Website https://www.canceriq.com/
- LinkedIn https://www.linkedin.com/company/cancer-iq-inc-/about/
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)